Anti-PD-1 and PD-L1 therapy for bladder cancer: What is on the horizon?

Future Oncology

Volumn 11, Issue 16, 2015, Pages 2299-2306

  Sundararajan, Srinath ^a   Vogelzang, Nicholas J ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

bladder cancer; immunotherapy; PD 1; PD L1

Indexed keywords

ATEZOLIZUMAB; BCG VACCINE; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; PROGRAMMED DEATH LIGAND 1 ANTIBODY; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER IMMUNOTHERAPY; HEALTH CARE QUALITY; HUMAN; IMMUNOSURVEILLANCE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84939161466     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.162     Document Type: Review

References (55)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65(1), 5-29 (2015).
2. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8 (6), 1050-1055 (1990).
3. Loehrer PJ, Sr., Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10 (7), 1066-1073 (1992).
4. Von Der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18(17), 3068-3077 (2000).
5. Sternberg CN, De Mulder PH, Schornagel JH et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol no. 30924. J. Clin. Oncol. 19(10), 2638-2646 (2001).
6. Sternberg CN, De Mulder P, Schornagel JH et al. Seven year update of an EORTC Phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer 42(1), 50-54 (2006).
7. Bellmunt J, Theodore C, Demkov T et al. Phase III trial of vinfunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 27(27), 4454-4461 (2009).
8. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superfcial bladder tumors. J. Urol. 116(2), 180-183 (1976).
9. Alexandroff AB, Jackson AM, O'donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 353 (9165), 1689-1694 (1999).
10. Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K. Mechanisms of action of intravesical Bacille Calmette-Guerin: local immune mechanisms. Clin. Infect. Dis. 31(Suppl. 3), S91-S93 (2000).
11. Bohle A, Brandau S. Immune mechanisms in Bacillus Calmette-Guerin immunotherapy for superfcial bladder cancer. J. Urol. 170 (3), 964-969 (2003).
12. Mungan NA, Witjes JA. Bacille Calmette-Guerin in superfcial transitional cell carcinoma. Br. J. Urol. 82(2), 213-223 (1998).
13. Nepple KG, Lightfoot AJ, Rosevear HM, O'donnell MA, Lamm DL, Bladder Cancer Genitourinary Oncology Study Group. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J. Urol. 184 (5), 1915-1919 (2010).
14. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271(12), 907-913 (1994).
15. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J. Clin. Oncol. 14(1), 7-17 (1996).
16. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13(3), 688-696 (1995).
17. Rosenberg SA, Lotze MT, Yang JC et al Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. 85(8), 622-632 (1993).
18. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734-1736 (1996).
19. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl Acad. Sci. USA 95(17), 10067-10071 (1998).
20. Agata Y, Kawasaki A, Nishimura H et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8(5), 765-772 (1996).
21. Keir ME, Freeman GJ, Sharpe AH. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J. Immunol. 179(8), 5064-5070 (2007).
22. Bennett F, Luxenberg D, Ling V et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J. Immunol. 170(2), 711-718 (2003).
23. Latchman Y, Wood CR, Chernova T et al. PD-l2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2(3), 261-268 (2001).
24. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specifc T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol. Immunother. 54(4), 307-314 (2005).
25. Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
26. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
27. Motzer RJ, Rini BI, McDermott DF et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trial. J. Clin. Oncol. 33(13), 1430-1437 (2014).
28. Kwon ED, Drake CG, Scher HI et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, Phase III trial. Lancet Oncol. 15(7), 700-712 (2014).
29. Topalian SL, Sznol M, Mcdermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32(10), 1020-1030 (2014).
30. Nanda R, Chow LQ, Dees EC et al. A Phase Ib study of pembrolizumab (MK-3475) in patients with advanced trip le-negative breast cancer. San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9-13 December 2014.
31. Brahmer JR, Horn L, Gandhi L et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (Pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014. Chicago, IL, USA, 30 May-3 June 2014.
32. US Food and Drug Administration-Pembrolizumab. www.Fda.Gov
33. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134-144 (2013).
34. Robert C, Ribas A, Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a Phase 1 trial. Lancet 384 (9948), 1109-1117 (2014).
35. Muro K, Bang Y, Shankaran V et al. Phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with advanced gastric cancer. Ann. Oncol. 25(Suppl. 4), Abstract Lba15a (2014).
36. Chow LQ, Burtness B, Weiss J et al. Phase Ib study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with human papiilloma virus (HPV)-positive and negative head and neck cancer (HNC). Ann. Oncol. 25(Suppl. 4), Abstract Lba31a (2014).
37. Garon E, Leighl N, Rizvi N, Blumenschein G, Balmanoukian A, Eder J. Safety and clinical activity of MK-3475 in previously treated patients (Pts) with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 32(15 Suppl.), 133339-133144 (2014).
38. Ribas A. Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma. Presented at: American Association for Cancer Research Annual Meeting. Philadelphia, PA, USA, 19-22 April 2015.
39. Hodi FS. Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared with ipilimumab alone. Presented at: American Association for Cancer Research Annual Meeting. Philadelphia, PA, USA, 19-22 April 2015.
40. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372(21), 2006-2017 (2015).
41. Emens L BF, Krop I et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Presented at: American Association for Cancer Research Annual Meeting. Philadelphia, PA, USA, 19-22 April 2015.
42. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression oF B7-H1 (PD-L1) signifcantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol. Immunother. 56(8), 1173-1182 (2007).
43. Inman BA, Sebo TJ, Frigola X et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109(8), 1499-1505 (2007).
44. Boorjian SA, Sheinin Y, Crispen PL et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin. Cancer Res. 14(15), 4800-4808 (2008).
45. Bellmunt J, Mullane SA, Werner L et al. Association of PD-L1 expression on tumor-infltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann. Oncol. 26 (4), 812-817 (2015).
46. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528), 563-567 (2014).
47. Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528), 558-562 (2014).
48. Plimack ER, Gupta S, Bellmunt J et al. Phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with advanced urothelial tract cancer. Ann. Oncol. 25(Suppl. 4), Abstract Lba23a (2014).
49. Clinical Trials Database: NCT02108652. https://clinicaltrials.gov
50. Clinical Trials Database: NCT02302807. https://clinicaltrials.gov
51. Clinical Trials Database: NCT01772004. https://clinicaltrials.gov
52. Clinical Trials Database: NCT02335424. https://clinicaltrials.gov
53. Clinical Trials Database: NCT02256436. https://clinicaltrials.gov
54. Clinical Trials Database: NCT02387996. https://clinicaltrials.gov
55. Clinical Trials Database: NCT02324582. https://clinicaltrials.gov